Evaluation of the VeriStrat (R) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

Basit Öğe Kaydı
dc.contributor.authorGadgeel, Shirish
dc.contributor.authorGoss, Glenwood
dc.contributor.authorSoria, Jean-Charles
dc.contributor.authorFelip, Enriqueta
dc.contributor.authorGeorgoulias, Vassilis
dc.contributor.authorLu, Shun
dc.contributor.authorCobo, Manuel
dc.contributor.authorSyrigos, Konstantinos
dc.contributor.authorLee, Ki Hyeong
dc.contributor.authorGoker, Erdem
dc.contributor.authorGuclu, Salih Z.
dc.contributor.authorIsla, Dolores
dc.contributor.authorMorabito, Alessandro
dc.contributor.authorDupuis, Nicholas
dc.contributor.authorBuehnemann, Claudia
dc.contributor.authorKraemer, Nicole
dc.contributor.authorSolca, Flavio
dc.contributor.authorEhrnrooth, Eva
dc.contributor.authorArdizzoni, Andrea
dc.date.accessioned2019-10-27T11:07:05Z
dc.date.available2019-10-27T11:07:05Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives: Identification of biomarkers associated with clinical benefit may be crucial in establishing optimal treatment choice for patients with squamous cell carcinoma (SCC) of the lung after first-line chemotherapy. In this study, the ability of the VeriStrat serum protein test to predict differential clinical benefit with afatinib versus erlotinib, and the association of VeriStrat status with clinical outcomes irrespective of EGFR-TKI used, was assessed in a retrospective analysis of the phase III LUX-Lung 8 trial. Materials and methods: Pretreatment plasma samples were analyzed using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Spectra were evaluated to assign a VeriStrat 'Good' (VS-G) or VeriStrat 'Poor' (VS-P) classification. Overall survival (OS), progression-free survival, and other endpoints were assessed with respect to pretreatment VeriStrat status; OS was the primary efficacy variable. Results: Of 795 patients randomized in LUX-Lung 8, 675 were classified (VS-G: 412; VS-P: 263). In the VS-G group, OS was significantly longer with afatinib versus erlotinib (HR 0.79 [95% CI: 0.63-0.98]). In the VS -P group, there was no significant difference in OS between afatinib and erlotinib (HR 0.90 [0.70-1.16]). However, there was no interaction between VeriStrat classification and treatment group for OS la interaction = 0.5303). OS was significantly longer in VS-G versus VS -P patients, both in the overall VeriStrat-classified population (HR 0.41 [0.35-0.49]) and afatinib-treated patients (HR 0.40 [0.31-0.51]). Multivariate analysis showed that VeriStrat was an independent predictor of OS in afatinib-treated patients, regardless of ECOG PS or best response to first line chemotherapy. Outcomes with other efficacy endpoints were similar. Conclusion: VS-G classification is strongly associated with favorable survival outcomes with either afatinib or erlotinib compared with VS-P classification. In VS-G patients, survival outcomes with afatinib are superior to those with erlotinib. VeriStrat classification may guide treatment decisions in patients with SCC of the lung.en_US
dc.description.sponsorshipBoehringer IngelheimBoehringer Ingelheimen_US
dc.description.sponsorshipThis study was funded by Boehringer Ingelheim. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and have approved the final version.en_US
dc.identifier.doi10.1016/j.lungcan.2017.05.010en_US
dc.identifier.endpage108en_US
dc.identifier.issn0169-5002
dc.identifier.issn1872-8332
dc.identifier.pmid28577938en_US
dc.identifier.startpage101en_US
dc.identifier.urihttps://doi.org/10.1016/j.lungcan.2017.05.010
dc.identifier.urihttps://hdl.handle.net/11454/31974
dc.identifier.volume109en_US
dc.identifier.wosWOS:000405152800017en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofLung Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAfatiniben_US
dc.subjectErlotiniben_US
dc.subjectSquamous cell carcinoma of the lungen_US
dc.subjectLUX-lung 8en_US
dc.subjectVeriStraten_US
dc.subjectBiomarkeren_US
dc.titleEvaluation of the VeriStrat (R) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu